NASDAQ:ARGX

argenx Stock Forecast, Price & News

$305.36

+18.36 (+6.40 %)

(As of 01/20/2021 04:33 PM ET)

Add

Compare

Today's Range

$286.39

Now: $305.36▼

$305.70

50-Day Range

$268.30

MA: $291.63▼

$308.36

52-Week Range

$103.75

Now: $305.36▼

$312.06

Volume321,922 shs

Average Volume173,685 shs

Market Capitalization$14.46 billion

P/E RatioN/A

Dividend YieldN/A

Beta1

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

MarketRank^™

Overall MarketRank^™

1.13 out of 5 stars

Medical Sector

883rd out of 1,928 stocks

Biological Products, Except Diagnostic Industry

114th out of 177 stocks

2.3 Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 12 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $266.81, argenx has a forecasted downside of 12.6% from its current price of $305.36.
Amount of Analyst Coverage
argenx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
argenx has received 504 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
argenx has received 498 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
argenx has received 50.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote “Outperform” if you believe ARGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Institutions
54.21% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to decrease in the coming year, from ($12.48) to ($13.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -64.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -64.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 9.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ARGX

Previous Symbol

CUSIPN/A

CIK1697862

Webwww.argenx.com

Phone329-310-3400

Employees186

Debt

Debt-to-Equity RatioN/A

Current Ratio9.90

Quick Ratio9.87

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$78.17 million

Price / Sales184.93

Cash FlowN/A

Price / Cash FlowN/A

Book Value$30.88 per share

Price / Book9.89

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares47,342,000

Market Cap$14.46 billion

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$305.36

+18.36 (+6.40 %)

(As of 01/20/2021 04:33 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

argenx (NASDAQ:ARGX) Frequently Asked Questions

How has argenx's stock been impacted by Coronavirus?

argenx's stock was trading at $133.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARGX stock has increased by 125.9% and is now trading at $302.27.
View which stocks have been most impacted by COVID-19.

Is argenx a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than argenx?

Wall Street analysts have given argenx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but argenx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as argenx's CEO?

1,428 employees have rated argenx CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among argenx's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for argenx.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) issued its quarterly earnings data on Thursday, October, 22nd. The company reported ($3.96) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.16. The company had revenue of $8.97 million for the quarter, compared to analysts' expectations of $18.08 million.
View argenx's earnings history.

What price target have analysts set for ARGX?

18 Wall Street analysts have issued twelve-month price objectives for argenx's shares. Their forecasts range from $160.00 to $350.00. On average, they anticipate argenx's share price to reach $266.81 in the next year. This suggests that the stock has a possible downside of 11.7%.
View analysts' price targets for argenx or view Wall Street analyst' top-rated stocks.

Who are some of argenx's key competitors?

Some companies that are related to argenx include Moderna (MRNA), Biogen (BIIB), Seagen (SGEN), BioNTech (BNTX), Novozymes A/S (NVZMY), CRISPR Therapeutics (CRSP), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Twist Bioscience (TWST), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Denali Therapeutics (DNLI) and Novavax (NVAX).
View all of ARGX's competitors.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

Who are argenx's key executives?

argenx's management team includes the following people:

Mr. Timothy Van Hauwermeiren M.B.A., M.Sc., MSc, EMBA, CEO & Exec. Director (Age 49)
Mr. Eric Castaldi, Chief Financial Officer (Age 57)
Mr. R. Keith Woods, Chief Operating Officer (Age 53)
Prof. Hans de Haard, Chief Scientific Officer (Age 61)
Mr. Dirk Marcel Leon Beeusaert L.L.M., Gen. Counsel (Age 57)
Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 36)
Dr. Wim Parys M.D., Chief Medical Officer (Age 61)
Joke Comijn, Director Corp. Communications & Investor Relations (EU)
Mr. Marc Schorpion, Global Head of HR
Ms. Andria Wilk, Global Head of Quality Assurance

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.01%) and Crossmark Global Holdings Inc. (0.01%).

Which major investors are buying argenx stock?

ARGX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Crossmark Global Holdings Inc..

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $302.27.

How big of a company is argenx?

argenx has a market capitalization of $14.31 billion and generates $78.17 million in revenue each year. The company earns $-182,520,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. argenx employs 186 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here